false
0001872812
0001872812
2024-05-01
2024-05-01
0001872812
TCBP:AmericanDepositarySharesEachRepresentingMember
2024-05-01
2024-05-01
0001872812
TCBP:OrdinarySharesNominalValue0.0001PerShareMember
2024-05-01
2024-05-01
0001872812
TCBP:WarrantsMember
2024-05-01
2024-05-01
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): May 1, 2024
TC
Biopharm (Holdings) PLC
(Exact
name of registrant as specified in charter)
Scotland |
|
001-41231 |
|
N/A |
(State
or other jurisdiction |
|
(Commission |
|
(IRS
Employer |
of
incorporation) |
|
File
Number) |
|
Identification
No.) |
Maxim
1, 2 Parklands Way, Holytown, Motherwell,
Scotland,
United Kingdom |
|
ML1
4WR |
(Address
of principal executive offices) |
|
(Zip
Code) |
Registrant’s
telephone number, including area code: +44 (0)
141 433 7557
Not
Applicable
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
American
Depositary Shares, each representing twenty Ordinary Shares, nominal value £0.0001 per share |
|
TCBP |
|
The
Nasdaq Stock Market LLC |
Ordinary
Shares, nominal value £0.0001 per share* |
|
N/A |
|
The
Nasdaq Stock Market LLC |
Warrants |
|
TCBPW |
|
The
Nasdaq Stock Market LLC |
*
Not for trading, but only in connection with the listing of the American Depositary Shares on The NASDAQ Stock Market LLC.
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☒
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
On
May 1, 2024, TC Biopharm (Holdings) PLC (the “Company”) entered into a non-binding letter of intent (the “LOI”)
with a private company (the “Seller”), regarding a potential business combination (the “Proposed Transaction”)
whereby the Company or a subsidiary of the Company would acquire the Seller. In connection with the Proposed Transaction, the Company
will pay to the Seller a cash purchase price equal to $20 million less any amounts payable on any Seller indebtedness and issue American
Depository Shares (the “ADSs”) representing a number of the Company’s ordinary shares (the “Shares”) where
the issue price of such Shares is equal to the average price paid in a fundraising from new and existing shareholders in the Company
raising in excess of US$50 million (the “Issue Price”), such that the total value attributable to the Shares at closing is
equal to US$20 million. In addition, the Seller will be entitled to certain payments upon satisfaction of various development milestones.
The
LOI only represents a mutual indication of interest regarding the Proposed Transaction and the terms of the Proposed Transaction are
subject to a number of contingencies, including the completion of customary due diligence and the negotiation and execution of definitive
agreements. Upon execution of the definitive agreements, the completion of the transaction will be subject to, among other matters, satisfaction
of the conditions negotiated therein, the Company having secured adequate financing, and receipt of all third party (including governmental)
approvals, licenses, consents, and clearances, as and when applicable. There can be no assurance that the Proposed Transaction will be
completed on the terms contemplated in the LOI or otherwise. In particular, the timing of closing of any such transaction and the aggregate
consideration that we may pay may materially differ from that currently contemplated by the LOI.
A
copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.
Forward-Looking
Statements
This
Current Report on Form 8-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of
1995. All statements contained in this Current Report on Form 8-K that do not relate to matters of historical fact should be considered
forward-looking statements, including without limitation statements regarding the Company’s intent or ability to effect any budget
savings or execute on any M&A or capital raising strategy. These statements are based on management’s current assumptions and
are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause the
Company’s actual results, performance or achievements to be materially different from any future results, performance or achievements
expressed or implied by the forward-looking statements, including that the proposed issuance of shares may not be approved by the Company’s
shareholders. For other important factors that could cause actual results to differ materially from the forward-looking statements in
this Current Report on Form 8-K, please see the risks and uncertainties identified under the heading “Risk Factors” in our
Annual Report on Form 10-K for the year ended December 31, 2023, and our other reports filed with the SEC, all of which is available
on the Company’s Investor Relations website at www.tcbiopharm.com and on the SEC website at www.sec.gov. All forward-looking statements
reflect the Company’s beliefs and assumptions only as of the date of this Current Report on Form 8-K. The Company undertakes no
obligation to update forward-looking statements to reflect future events or circumstances.
Item 9.01. |
Financial Statements and Exhibits. |
(d)
Exhibits
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
Date:
May 6, 2024 |
|
|
TC
BIOPHARM (HOLDINGS) PLC |
|
|
|
By: |
/s/
Martin Thorp |
|
|
Martin
Thorp |
|
|
Chief
Financial Officer |
Exhibit
99.1
TC
BioPharm Announces Execution of Second Non-Binding Letter of Intent for Acquisition, Targeting Innovative CAR-T Therapies
Acquisition
target has established proof of concept data demonstrating the therapeutic potential for the treatment
of multiple solid tumors
EDINBURGH,
Scotland, May 06, 2024 — TC BioPharm (Holdings) PLC (“TC BioPharm” or the “Company”) (NASDAQ: TCBP) a clinical
stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced
the execution of a non-binding letter of intent to acquire a privately-held biotechnology company pursuing the development of innovative
Chimeric Antigen Receptor T-cell (CAR-T) therapies for the treatment of refractory cancers and solid tumors.
This
agreement is the second such agreement in as many months shows TCBP’s commitment to its M&A strategy aimed at expanding its
therapeutic platform.
CAR
T-cell therapy modifies a patient’s own immune cells to provide a heightened ability to identify and eliminate cancer cells.
The
target acquisition has developed a number of proprietary approaches to re-engineer CARs to better target solid tumors. The Company has
generated pre-clinical proof of concept data that demonstrates the therapeutic potential of its lead CAR-T candidate for a range of solid
tumors including colorectal, pancreatic, mesothelioma, ovarian and breast cancer. In addition, the target acquisition is also developing
a novel, allogeneic CAR-T for the treatment of autoimmune diseases.
There
can be no assurance that a definitive agreement will be executed or that the proposed transaction will be consummated on the terms or
timeframe currently contemplated. Upon execution of the definitive agreements, the completion of the transaction will be subject to,
among other matters, satisfaction of the conditions negotiated therein, the Company having secured adequate financing, and receipt of
all third party (including governmental) approvals, licenses, consents, and clearances, as and when applicable.
“Management
is extremely pleased to announce this second potential acquisiton which will provide strong advantages to our current therapeutic platform
as well as expand our efforts into autoimmune disease,” said Mr. Bryan Kobel, CEO of TC BioPharm. “There are substantial
synergies between the two companies with extensive benefits to the business combination including CAR development expertise as well as
gamma delta and alpha beta T-cells. Our existing expertise in gamma delta T-cells as well as transitioning processes and therapeutics
from autologous to allogeneic will be impactful in advancing the solid tumor assets of the acquisition, the acquired company brings strong
CAR engineering expertise to help us further develop our co-stimulatory CAR as well as a strong clinical team. We believe that the combination
of these two companies provides a well balanced platform for investors and patients in our pursuit of creating next-generation cell therapies
for the treatment of multiple indications. This represents not only multiple shots on goal, but an expanded asset base in several immune
responder cells for the treatment of a wide range of disease with an extensive patent portfolio. As such, 2024 and 2025 could now have
inflections points for data in several pipeline assets in a variety of indications. I am proud of our ability to navigate a difficult
capital market environment and identify complimentary resources that will continue to enhance the overall value of our company and look
forward to working with our expanded team.”
Forward-Looking
Statements
This
press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements
contained in this Current Report on Form 8-K that do not relate to matters of historical fact should be considered forward-looking statements,
including without limitation statements regarding the Company’s intent or ability to effect any budget savings or execute on any
M&A or capital raising strategy. These statements are based on management’s current assumptions and are neither promises nor
guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause the Company’s actual
results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied
by the forward-looking statements. For other important factors that could cause actual results to differ materially from the forward-looking
statements in this Current Report on Form 8-K, please see the risks and uncertainties identified under the heading “Risk Factors”
in our Annual Report on Form 10-K for the year ended December 31, 2023, and our other reports filed with the SEC, all of which is available
on the Company’s Investor Relations website at www.tcbiopharm.com and on the SEC website at www.sec.gov. All forward-looking statements
reflect the Company’s beliefs and assumptions only as of the date of this Current Report on Form 8-K. The Company undertakes no
obligation to update forward-looking statements to reflect future events or circumstances.
About
TC BioPharm (Holdings) PLC
TC
BioPharm is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cell
therapies for the treatment of cancer with human efficacy data in acute myeloid leukemia. Gamma-delta T cells are naturally occurring
immune cells that embody properties of both the innate and adaptive immune systems and can intrinsically differentiate between healthy
and diseased tissue.
TC
BioPharm is the leader in developing gamma-delta T cell therapies, and the first company to conduct phase II/pivotal clinical studies
in oncology. The Company is conducting two investigator-initiated clinical trials for its unmodified gamma-delta T cell product line
- Phase 2b/3 pivotal trial for OmnImmune® in treatment of acute myeloid leukemia using the Company’s proprietary allogeneic
CryoTC technology to provide frozen product to clinics worldwide.
Contact:
Chris
Camarra
EVP
Communications
c.camarra@tcbiopharm.com
v3.24.1.u1
Cover
|
May 01, 2024 |
Document Type |
8-K
|
Amendment Flag |
false
|
Document Period End Date |
May 01, 2024
|
Entity File Number |
001-41231
|
Entity Registrant Name |
TC
Biopharm (Holdings) PLC
|
Entity Central Index Key |
0001872812
|
Entity Address, Address Line One |
Maxim
1
|
Entity Address, Address Line Two |
2 Parklands Way
|
Entity Address, Address Line Three |
Holytown
|
Entity Address, City or Town |
Motherwell
|
Entity Address, Country |
GB
|
Entity Address, Postal Zip Code |
ML1
4WR
|
City Area Code |
+44 (0)
141
|
Local Phone Number |
433 7557
|
Written Communications |
false
|
Soliciting Material |
false
|
Pre-commencement Tender Offer |
false
|
Pre-commencement Issuer Tender Offer |
false
|
Entity Emerging Growth Company |
true
|
Elected Not To Use the Extended Transition Period |
false
|
American Depositary Shares, each representing |
|
Title of 12(b) Security |
American
Depositary Shares, each representing twenty Ordinary Shares, nominal value £0.0001 per share
|
Trading Symbol |
TCBP
|
Security Exchange Name |
NASDAQ
|
Ordinary Shares, nominal value £0.0001 per share* |
|
Title of 12(b) Security |
Ordinary
Shares, nominal value £0.0001 per share*
|
Trading Symbol |
N/A
|
Security Exchange Name |
NASDAQ
|
Warrants |
|
Title of 12(b) Security |
Warrants
|
Trading Symbol |
TCBPW
|
Security Exchange Name |
NASDAQ
|
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 2 such as Street or Suite number
+ References
+ Details
Name: |
dei_EntityAddressAddressLine2 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 3 such as an Office Park
+ References
+ Details
Name: |
dei_EntityAddressAddressLine3 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionISO 3166-1 alpha-2 country code.
+ References
+ Details
Name: |
dei_EntityAddressCountry |
Namespace Prefix: |
dei_ |
Data Type: |
dei:countryCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 13e -Subsection 4c
+ Details
Name: |
dei_PreCommencementIssuerTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14d -Subsection 2b
+ Details
Name: |
dei_PreCommencementTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the Exchange on which a security is registered.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1
+ Details
Name: |
dei_SecurityExchangeName |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarExchangeCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Section 14a -Number 240 -Subsection 12
+ Details
Name: |
dei_SolicitingMaterial |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 425
+ Details
Name: |
dei_WrittenCommunications |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=TCBP_AmericanDepositarySharesEachRepresentingMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=TCBP_OrdinarySharesNominalValue0.0001PerShareMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=TCBP_WarrantsMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
TC BioPharm (NASDAQ:TCBPW)
Historical Stock Chart
From Apr 2024 to May 2024
TC BioPharm (NASDAQ:TCBPW)
Historical Stock Chart
From May 2023 to May 2024